TomoRx

Drug Profile

TomoRx

Latest Information Update: 21 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImaRx Therapeutics
  • Class Contrast media
  • Mechanism of Action Emission-computed tomography enhancers; Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 21 Oct 2002 Discontinued - Preclinical for Gastrointestinal disorders diagnosis in USA (PO)
  • 16 Nov 1998 No development reported - Preclinical for Gastrointestinal disorders diagnosis in USA (PO)
  • 03 Sep 1996 Preclinical development for Gastrointestinal disorders diagnosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top